R

Rigel Pharmaceuticals
D

RIGL

16.740
USD
-0.31
(-1.82%)
Market Open
Volume
856
EPS
0
Div Yield
-
P/E
62
Market Cap
294,875,770
OverviewSignalsIdeasNews
Related Instruments
    AMGN
    AMGN
    -1.57
    (-0.60%)
    261.93 USD
    BMY
    BMY
    -0.330
    (-0.58%)
    56.950 USD
    GILD
    GILD
    -0.050
    (-0.05%)
    92.520 USD
    I
    INCY
    0.430
    (0.62%)
    69.340 USD
    LLY
    LLY
    13.61
    (1.77%)
    779.79 USD
    MRK
    MRK
    0.160
    (0.16%)
    98.350 USD
    PFE
    PFE
    -0.035
    (-0.13%)
    26.325 USD
    REGN
    REGN
    9.21
    (1.31%)
    711.81 USD
    More
News

Title: Rigel Pharmaceuticals Inc

Sector: Healthcare
Industry: Biotechnology
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.